Check out our most popular compounded medications! Get Started
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded rinse containing morphine sulfate, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved. Morphine is a Schedule II controlled substance.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing morphine are listed in tablet, capsule, solution and injection forms. No morphine product of any kind is listed in rinse form.
This dose form is water-containing (aqueous). Under USP <795>, aqueous preparations carry shorter default beyond-use dates than nonaqueous ones, and a preservative in the base allows a longer date than no preservative. The date printed on the label is the one to follow.
Morphine is a Schedule II opioid pain reliever that compounding pharmacies prepare by prescription in several dosage forms.
Morphine is an opioid analgesic. It is a full agonist that acts mainly on mu-opioid receptors and changes how the brain and nervous system respond to pain. Manufactured forms include oral solution, immediate-release tablets, extended-release tablets and capsules, and injections. MS Contin extended-release tablets are FDA-approved for severe and persistent pain that requires an opioid analgesic and cannot be adequately treated with alternative options, including immediate-release opioids; MS Contin is not indicated for as-needed use. StatPearls notes that injectable morphine is also approved for epidural and intrathecal use. A prescriber might order morphine compounded when a patient needs a strength, dosage form or vehicle that is not manufactured, such as one free of a specific allergen. Compounded preparations are not FDA-approved and require a prescription. Morphine is a federally controlled Schedule II substance.
MS Contin carries a boxed warning covering addiction, abuse and misuse; life-threatening breathing problems, especially when starting or after a dose increase, and the need to swallow tablets whole; fatal accidental ingestion, especially by children; profound sedation, breathing problems, coma or death with benzodiazepines, alcohol or other CNS depressants; neonatal opioid withdrawal syndrome; and the opioid REMS program. Do not use it with significant breathing problems, acute or severe asthma without monitoring, known or suspected bowel blockage, an MAO inhibitor taken within the past 14 days, or a morphine allergy. Other label warnings include adrenal insufficiency, severe low blood pressure, seizures, opioid-induced hyperalgesia, withdrawal and impaired driving. Morphine passes into breast milk; LactMed notes newborns are particularly sensitive to opioids and says extended-release morphine products are not recommended while nursing. Talk to your prescriber or pharmacist about side effects.
Morphine is a full opioid agonist, relatively selective for the mu receptor, with no ceiling effect for analgesia (MS Contin label). Oral bioavailability is about 20 to 40% because of presystemic metabolism in the gut wall and liver. Morphine is 30 to 35% reversibly bound to plasma proteins, with a volume of distribution of about 3 to 4 L/kg. Glucuronidation yields morphine-3-glucuronide (about 50%), which has no significant analgesic activity, and morphine-6-glucuronide (about 5 to 15%), which is analgesic but crosses the blood-brain barrier poorly. Elimination is mainly renal as M3G, with about 10% excreted unchanged; the label gives a half-life of 2 to 4 hours after intravenous dosing and a terminal half-life of about 15 hours in studies with longer sampling. Labeled indication (MS Contin): severe and persistent pain requiring an opioid analgesic when alternatives, including immediate-release opioids, are inadequate; not an as-needed analgesic. Dosing is per prescriber. Monitor respiratory status, sedation, misuse, bowel function, and hepatic and renal function. Morphine is Schedule II. Electronic prescribing of controlled substances is voluntary under federal DEA rules, CMS applies a prescriber-level threshold for Part D, and a number of states mandate it.
Measure the amount shown on your label with the cup or syringe provided. Swish it around your mouth for the time on your label, often 30 seconds or longer, then spit it out unless your label says to swallow. Do not eat, drink or rinse with water for a while afterward as directed. Shake the bottle first if your label says to.
Oral rinses are aqueous. Under USP <795>, a preserved rinse usually carries a beyond-use date of up to 35 days at room temperature or refrigerated, and an unpreserved one 14 days refrigerated. Your label states whether to refrigerate and the beyond-use date. Keep out of reach of children and discard after that date.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
This preparation is a controlled substance. Additional prescribing, refill, and shipping restrictions apply, and the states Bayview can dispense it to are narrower than for non-controlled preparations.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Swish in mouth, hold as directed and then expectorate
